AHIA
REGN icon

Andrew Hill Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Andrew Hill Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,091
Closed -$688K – 177
2021
Q4 		$688K Buy
+1,091
New +$671K 0.64% 37

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Andrew Hill Investment Advisors's REGN Position: Q1 2022 in Review

Andrew Hill Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 1,091 shares — an estimated $688K sold.

Andrew Hill Investment Advisors first reported a position in REGN in Q4 2021 and held it in 1 quarter. The position peaked at $688K in Q4 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

  • Andrew Hill Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Andrew Hill Investment Advisors sold 1,091 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $688K.
  • Andrew Hill Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Andrew Hill Investment Advisors's Regeneron Pharmaceuticals position peaked at $688K in Q4 2021.
  • 1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on Andrew Hill Investment Advisors's 13F filing for Q1 2022, filed 11 May 2022.